Worth reading
24Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
-159
¥ millionWording
Conditional
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportThird quarter of the fiscal year ending June 20264 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥1,107 million-12.6%
Operating profit¥208 million-41.1%
Ordinary income¥209 million-38.8%
Net income¥165 million-45.6%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
The bio-manufacturing support services exceeded the initial sales targetNew initiatives
- Launch of bio-manufacturing support services
Segment results
- Life Science research support services (LSS)Net Sales771Year-on-year (%)-22.5
- Functional materials development support services (FDS)Net Sales228Year-on-year (%)-16.1
- Bio-manufacturing support services (BMS)Net Sales107Year on year against the same period last yearNo prior-year results
Number of employees
Number of Employees62 People
StandardAs of June 2025
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | Third quarter of the fiscal year ending June 2026 |
| Net Sales | ¥1,107 million (YoY -12.6%) |
| Operating profit | ¥208 million (YoY -41.1%) |
| Ordinary income | ¥209 million (YoY -38.8%) |
| Net income | ¥165 million (YoY -45.6%) |
| Self-assessment against the plan | The bio-manufacturing support services exceeded the initial sales target |
| Segment results | Segment Life Science research support services (LSS) / Net Sales ¥771 million / Year-on-year (%) ¥-22.5 million, Segment Functional materials development support services (FDS) / Net Sales ¥228 million / Year-on-year (%) ¥-16.1 million, Segment Bio-manufacturing support services (BMS) / Net Sales ¥107 million / Year on year against the same period last year No prior-year results |
| Number of employees | Number of Employees 62 People / Standard As of June 2025 |
| New initiatives | Launch of bio-manufacturing support services |
Items this document does not state (21)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastBreakdown of Factors Affecting the ChangeKey KPIsUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This was mainly because large projects in the domestic academia sector declined significantly and the overseas business also remained sluggish. In the functional materials development support services, revenue recognition for projects was pushed back to the fourth quarter due to customers' schedules for large-scale clinical trials.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.